We are live on
!
Find out more
BE
Bonness Enterprises Portfolio holdings
AUM
$310M
1-Year Est. Return
24.22%
This Fund
S&P 500
This Quarter
Est. Return
+5.61%
1 Year Est. Return
+24.22%
3 Year Est. Return
+94.56%
5 Year Est. Return
+137.52%
10 Year Est. Return
+441.57%
AUM
$199M
AUM Growth
+$11.6M
(+6.2%)
Cap. Flow
+$1.99M
Cap. Flow
% of AUM
1%
Top 10 Holdings %
Top 10 Hldgs %
63.28%
Holding
40
New
1
Increased
3
Reduced
2
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$1.21M |
| 2 |
AT&T
T
|
+$485K |
| 3 |
Unilever
UL
|
+$361K |
| 4 |
Organon & Co
OGN
|
+$229K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$248K |
| 2 |
Philips
PHG
|
+$47K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 31.62% |
| 2 | Healthcare | 28.98% |
| 3 | Technology | 24.27% |
| 4 | Industrials | 4.38% |
| 5 | Consumer Staples | 4.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Progressive
PGR
$124B
| $56.2M | 28.32% |
572,608
| – | – |
|
2
Stryker
SYK
$128B
| $17.8M | 8.95% |
68,400
| – | – |
|
3
Microsoft
MSFT
$3.64T
| $12.6M | 6.33% |
46,400
| – | – |
|
4
Apple
AAPL
$4.49T
| $7.53M | 3.79% |
54,940
| – | – |
|
5
Johnson & Johnson
JNJ
$605B
| $6.42M | 3.23% |
38,938
| – | – |
|
6
Thermo Fisher Scientific
TMO
$216B
| $5.75M | 2.9% |
11,400
| – | – |
|
|
7
Merck
MRK
$317B
| $5.41M | 2.72% |
69,500
-3,336
| -5% | -$248K |
|
8
Intel
INTC
$444B
| $4.99M | 2.51% |
88,950
| – | – |
|
9
Nucor
NUE
$57.5B
| $4.54M | 2.29% |
47,350
| – | – |
|
10
Applied Materials
AMAT
$399B
| $4.46M | 2.24% |
31,300
| – | – |
|
|
11
Unilever
UL
$138B
| $4.45M | 2.24% |
67,591
+5,422
| +9% | +$361K |
|
12
Cisco
CSCO
$454B
| $4.39M | 2.21% |
82,900
| – | – |
|
13
IBM
IBM
$214B
| $4.32M | 2.17% |
30,819
| – | – |
|
14
Emerson Electric
EMR
$84.6B
| $4.19M | 2.11% |
43,500
| – | – |
|
15
AbbVie
ABBV
$434B
| $4.12M | 2.08% |
36,600
| – | – |
|
16
Abbott
ABT
$187B
| $3.79M | 1.91% |
32,700
| – | – |
|
|
MRSH
17
Marsh
MRSH
$92.2B
| $3.63M | 1.83% |
25,800
| – | – |
|
18
Bristol-Myers Squibb
BMY
$132B
| $3.55M | 1.79% |
53,100
| – | – |
|
19
United Parcel Service
UPS
$89.7B
| $3.11M | 1.57% |
14,950
| – | – |
|
20
Pfizer
PFE
$143B
| $3.08M | 1.55% |
78,608
| – | – |
|
21
John Wiley & Sons Class A
WLY
$2.75B
| $2.91M | 1.47% |
48,400
| – | – |
|
22
Agilent Technologies
A
$39.4B
| $2.65M | 1.33% |
17,900
| – | – |
|
|
23
AT&T
T
$162B
| $2.56M | 1.29% |
117,704
+21,317
| +22% | +$485K |
|
|
24
GSK
GSK
$103B
| $2.56M | 1.29% |
51,360
+25,120
| +96% | +$1.21M |
|
25
Corning
GLW
$121B
| $2.31M | 1.16% |
56,400
| – | – |
|
Similar funds
IPW
TL
RGC
IR
TWM
PH
CCG
FI
Bonness Enterprises's Q2 2021 Portfolio in Review
As of Q2 2021, Bonness Enterprises held 40 positions worth $199M, up 6.2% from $187M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Trading was light in Q2 2021: portfolio turnover was 2.5%. Bonness Enterprises opened 1 new position and made no exits, leaving the 40-position portfolio largely intact.
By sector, the portfolio is most concentrated in Financials at 32% of assets, down from 32% a quarter earlier, followed by Healthcare and Technology.
- Bonness Enterprises's largest Q2 2021 buy was Organon & Co: 6,950 shares worth $210K.
- Bonness Enterprises added most to GSK in Q2 2021, an estimated $1.21M increase.
- Bonness Enterprises's biggest Q2 2021 reduction was Merck, cutting an estimated $248K.
- Bonness Enterprises's ten largest holdings make up 63% of its $199M portfolio in Q2 2021.
- Bonness Enterprises opened 1 new position and closed 0 in Q2 2021.
- Bonness Enterprises's portfolio value rose 6.2% quarter-over-quarter to $199M.
Based on Bonness Enterprises's 13F filing for Q2 2021, filed 13 Jul 2021.